Amanta Healthcare Limited · NSE:AMANTA
Amanta Healthcare — Q4 FY26 Earnings Presentation
34 slides from Amanta Healthcare's earnings presentation, May 19, 2026
Slide 1: Cover letter to stock exchanges
Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 May 19, 2026 To, To, Sr. General Manager Sr. General Manager
Slide 2: Q4 & FY26 Investor Presentation
Amanta Healthcare Limited Q4 & FY26 Investor Presentation May, 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Amanta Healthcare Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: 30+ Years of Sterile Liquids Legacy
N I C HE PHA R MA C E U T I CA L C OM PA N Y OP E R AT I ON AL M E TR I C S FI N ANCI A L METR I CS 1 47 RE VE NUE CAGR E BI T DA CAGR 7 30+ Years of WHO-GMP facility Production lines Product portfolio 11% FY21–26 10% FY21–26 Sterile Liquids 6 320 21 R OE R OC E Legacy Therapeutic segments Distribut
Slide 5: Built to scale – Amanta's differentiated business model
Built to scale – Amanta’s differentiated business model RM Sourcing Manufacturing Capabilities 3 Channel Distribution Key materials Sourced Manufacturing facility in Gujarat spanning 66,852 sq. mts Robust sales and distribution team with 18.5% strong presence across the globe LVP 4 lines SVP 3 lines
Slide 6: Solutions: A Diverse Product Portfolio (1/2)
Solutions : A Diverse Product Portfolio (1/2) Types of IV Fluids : Notable Formulations : Diluent Product Overview : Dextrose, Normal Saline, Combination Of Ciprofloxacin, Metronidazole, Ofloxacin, • Plain Water for Injection (WFI) Dextrose Normal Saline, Ringer Lactate, Paracetamol, Fluconazole. •
Slide 7: Solutions: A Diverse Product Portfolio (2/2)
Solutions : A Diverse Product Portfolio (2/2) Applications : Applications : Product Types : Administered through nebulisers for the treatment Treatment for Infections, Glaucoma, OTC Eye Lubricants of lungs affected by Asthma or Bronchiectasis Inflammation. Wound Cleaning Solutions Dosage Form : Dosa
Slide 8: Core Competitive Advantages Driving Success
Core Competitive Advantages PR ODU CTS & M AR KE TS DI S T R IB U T I ON Driving Success Well-established Wide Domestic & Pharma Manufacturer Global Network 47 Products Six therapeutic segments and container systems. 47 Pan-India network of 320 distributors, 96 sales staff, products registered in 12
Slide 9: Differentiated Manufacturing Technologies to Market End Product
Differentiated Manufacturing Technologies to Market End Product First to bring ISBM technology to India TE CHN OL OGY 01 TE CHN OL OGY 02 S U PP O RT S Y ST EM Aseptic Blow Injection Stretch- F&D Capability Fill Seal (ABFS) Blow Moulding (ISBM) Technology Technology In - house Product development FF
Slide 10: Growth Levers
Growth Levers T HR E E S T R AT E GI C P I L L A RS 01 02 03 M ARKET DEP TH M A NU F A CTU R IN G EFFICIENCY Wallet Share Capacity Green Energy Expansion Expansion & Cost Optimisation Complex dosages and niche molecules Scaling high-margin SteriPort and SVP Solar captive power plant of 10.8 MW acros
Slide 11: Our Flagship Product: SteriPort (LVP)
Our Flagship Product A First in India to shift from BFS → ISBM · Dominant in PP IV bottle segment SteriPort (LVP) Expansion in Capacity (In Cr.) 6.62 Cr 91% 44% 100–1000ml New line, Same Plant = Bottles Capacity Revenue Full Range Fixed cost leverage Capacity Utilization Contribution In-house achiev
Slide 12: SVP (Ready to move up the value chain)
High Margin Product SVP (Ready to move up the value chain) A SVP Expansion in Capacity (Qty Cr.) • An export centric segment 31.7 • Capacity tripled in 2008 20.9 • Incremental capacity is targeted at growing Inhalation Solution portfolio (Respules), OTC portfolio and Preservative Free unit doses. •
Slide 13: Excellent Manufacturing Facilities
Excellent Manufacturing Facilities Location: Certifications & Compliance: Production Capabilities: Block No: 872B, 873A, 874, 876 • ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO • Injections and 877 village Hariyala, District 45001:2018, WHO-GMP certified. • Sterile Liquids Kheda Gujarat, India
Slide 14: Sweating the assets to peak capacity
Sweating the assets to peak capacity Utilization % across each Parenteral Capex to drive future growth 130 91 90 73 83 99 98 89 94 91 93 97 93 25 FY23 FY24 FY25 FY26 12 10 6 LVP SVP Steriport Capex (INR Cr) FY26 Installed capacity FY23 FY24 FY25 FY26P FY27P (Units in crs) LVP (excluding SteriPort) 5
Slide 15: Increased Focus on exports – Driving higher margins
Increased Focus on exports – Driving higher margins 32% of revenue 68% of revenue Export markets 21 countries as of Fiscal 2025. Sales focus Domestic branded generics sold under proprietary brand names. Product range • LVP Pack Solutions: IV solutions, anti-fungal, and anti-protozoal formulations. •
Slide 16: De-leveraging in overdrive: Debt-to-Equity ratio reduced
De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 70% since FY23 • Reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs). (In Times) (In Times) Debt Service Coverage Ratio Debt to Equity Ratio 1.19 0.76 0.
Slide 17: Captive Solar Power Plant 10.8 MW
Captive Solar Power Plant 10.8 MW Under implementation to structurally lower power costs T O T A L PR O JE CT C O ST A N N U AL SA V IN G S PA Y B A C K PE R I O D INR 34.8 Cr INR 9 Cr 3.6 yrs Largely debt-funded Power cost reduction Pre-interest basis Key Watch Points Q1 FY27 commissioning INR 5.8
Slide 18: Leadership: The Board Of Directors
Leadership: The Board Of Directors Mr. Bhavesh Patel Mr. Pratik Gandhi Mr. Nimesh Patel Chairman and Managing Director Non-Executive Director Non-Executive Director 30+ Years Of Experience 10+ Years Of Experience 3+ Years Of Experience Bhavesh Patel is the Chairman and Pratik Gandhi is the Non-Execu
Slide 19: Leadership: The Board Of Directors
Leadership: The Board Of Directors Ms. Anjali Choksi Mr. Kshitij Patel Mr. Nitin Jain Independent Director Independent Director Independent Director 15+ Years Of Experience 25+ Years Of Experience 20+ Years Of Experience Anjali Choksi is an Independent Director of Kshitij Patel is the Independent an
Slide 20: Financial Performance – Q4 & FY26
Financial Performance – Q4 & FY26 (Figures in INR Cr.) Revenue EBITDA and Margins (%) PAT and Margins (%) 77 18 17 6 4 72 24% 22% 6% 7% Q4FY25 Q4FY26 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Revenue EBITDA and Margins (%) PAT and Margins (%) 288 61 63 15 50 11 40 30 275 20 10 4.0% 5.0% 22.0% 22.0% 0 FY25 FY26 FY
Slide 21: Strategic Highlights
Strategic Highlights Profitability increased by 42% in FY26 on YoY basis Sustained revenue trajectory: Q4FY26 revenue stood at INR 77 cr, registering a 7% YoY growth, while FY26 revenue reached INR 288 cr, marking a 5% YoY increase, reflecting consistent growth. Operational discipline sustains EBITD
Slide 22: Revenue Breakdown – Annual performance
Revenue Breakdown – Annual performance (Figures in Rs. crs) Revenue from operations FY26 FY25 FY24 FY23 Revenue from contract with customers : Sale of products 282 267 272 253 Sale of services 3 5 6 5 Sub- total 284 272 278 258 Other operating revenue : Scrap sales 2 1 1 1 Export incentives 2 1 0 1
Slide 23: Profit and Loss Statement
Profit and Loss Statement (Figures in Rs. crs) Particulars FY26 FY25 FY24 FY23 Revenues 288 275 280 259 Other Income 3 1 1 4 Total Income 291 276 282 263 Cost of materials consumed 97 101 86 101 Purchases of stock-in-trade 11 12 2 1 Changes in inventories of finished goods, work-in-process and stock
Slide 24: Balance Sheet
Balance Sheet (Figures in Rs. crs) Assets FY26 FY25 FY24 FY23 Equities & Liabilities FY26 FY25 FY24 FY23 Non-Current Assets Equity share capital 39 29 27 27 Property, plant and 197 208 223 229 Other Equity 181 68 40 36 equipment Capital work-in-progress 82 7 - - Net Worth 220 96 66 63 Right-of-use a
Slide 25: Cash Flow Statement
Cash Flow Statement (Figures in Rs. crs) Particulars FY26 FY25 FY24 FY23 Cashflow from Operating Activities 48 47 58 43 Cashflow from Investing Activities (94) (25) (10) (7) Cashflow from Financing Activities 126 (24) (46) (42) Cash and Cash Equivalents as at end of 81 0.2 1.5 0.1 period/Year 24
Slide 26: Annexure – Our Product Categories
Annexure Our Product Categories -
Slide 27: Fluid Therapy - (IV Fluid)
Fluid Therapy - (IV Fluid) Types of IV Fluids : • Dextrose • Normal Saline • Combination Of Dextrose Normal Saline • Ringer Lactate • Electrolytes Packaging Of Product : • Single Port container • Two Port container Fill Volume Options : • 100ml • 250ml • 500ml • 1000ml Innovative Technology : • Ster
Slide 28: Formulations
Formulations Product Focus : Fill Volume Range : • Injectables • 2ml to 100ml Therapeutic Products • Ophthalmic Segments • Respiratory Anti - fungal Fluconazole Technology : • Aseptic Blow-Fill- Seal (ABFS) & Notable Formulations: Injection Stretch Blow Moulding Anti – Pyretic Paracetamol (ISBM) tec
Slide 29: Diluents & Injectables
Diluents & Injectables Key Products : Pack Sizes : • Lidocaine • Offered in 5 ml & 10ml • Potassium Chloride Products : • Magnesium Sulphate • Sterile Water forInjection (WFI) • Calcium Chloride • Normal Saline WFI • Calcium Gluconate Injectables Portfolio Diluents Overview 28
Slide 30: Ophthalmic
Ophthalmic Dosage Form : Therapeutic Product • 5ml & 10ml segments Ciprofloxacin Ophthalmic Solution U.S.P. Ophthalmic (FFS) (0.3 % w/v) Applications : Timolol Maleate Eye Drops B.P.(0.5 % w/v & Ophthalmic (FFS) • Including treatment for Infections, 0.25 % w/v) Applications: Packaging Options: Glauc
Slide 31: Respiratory Solutions
Respiratory Solutions Dosage Form : • Available in 2.5ml Applications : • Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis. Key Product : • Budesonide Respiratory Suspension • Salbutamol Respiratory Solution • Salbutamol & Ipratropium Bromide Respirator
Slide 32: Irrigation Solutions
Irrigation Solutions Product Types : • OTC Eye Lubricants • Wound Cleaning Solutions Dosage Forms : • Available in 5ml, 10 ml & 20 ml Product : • Sodium Chloride Eye Wash • Wound Cleaning 31
Slide 33: Glossary
Glossary LVP: Large Volume Parenteral SVP: Small Volume Parenteral ABFS: Aseptic Blow Fill Seal ISBM: Injection Stretch-Blow Moulding WFI: Water For Injection SWFI: Sterile Water For Injection WHO-GMP: WHO - Good Manufacturing Practices PICs: Pharmaceutical Inspection Co-operation Scheme ISO: Intern
Slide 34: Investor Relations
Investor Relations Go India Advisors Amanta Healthcare Ltd. Name: Ms. Soumya Chhajed 8th Floor, Shaligram Corporates, Tel: +91-8619707750 C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India. Email:soumya@goindiaadvisors.com Telephone: 079 6777 7600 Name: Ms. Shrutee Barve Email Id: cs@amanta.co.in Te